Norberto Santana-Rodríguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Norberto Santana-Rodríguez has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Bernardino Clavo
Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain
20 shared publications Pedro Llontop
Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS)-BioPharm Group, ULPGC, Spain; Experimental Surgery, Research Unit, Hospital Dr. Negrín, Las Palmas de Gran Canaria, Spain
10 shared publications- Leandro Fernández-Pérez
Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Farmacología Molecular y Traslacional, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
6 shared publications Dominga Gutierrez
Radiation Oncology, Dr. Negrin University Hospital, 35.010 Las Palmas, Spain ; Canary Islands Institute for Cancer Research (ICIC), 35.010 Las Palmas, Spain
5 shared publicationsJ. Freixinet Gilart
Servicios de Cirugía Torácica. Hospital Universitario de Gran Canaria Dr. Negrín. Las Palmas de Gran Canaria
5 shared publicationsMaría D. Fiuza
Hospital Universitario Dr. Negrin
5 shared publications
Latest Publications
- 1 December 2023
- Published by AME Publishing Company in ASVIDE
- Vol. 10, 279
Parietal pleurectomy.
- 1 December 2023
- Published by AME Publishing Company in ASVIDE
- Vol. 10, 281
The risk of parenchymal air leak is higher than decortication for stage III empyema, and prolonged air leak should be expected as shown.
- 1 December 2023
- Published by AME Publishing Company in ASVIDE
- Vol. 10, 281
The risk of parenchymal air leak is higher than decortication for stage III empyema, and prolonged air leak should be expected as shown.
- 1 January 2023
- Published by Springer Nature
- p. 209-215
S6 + S10 Bisegmentectomy
- Open Access
- 10 March 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (6) , 2802
Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial
(1) Background: Chemotherapy-induced peripheral neuropathy (CIPN) decreases the quality of life of patients and can lead to a dose reduction and/or the interruption of chemotherapy treatment, limiting its effectiveness. Potential pathophysiological mechanisms involved in the pathogenesis of CIPN include chronic oxidative stress and subsequent increase in free radicals and proinflammatory cytokines. Approaches for the treatment of CIPN are highly limited in their number and efficacy, although several antioxidant-based therapies have been tried. On the other hand, ozone therapy can induce an adaptive antioxidant and anti-inflammatory response, which could be potentially useful in the management of CIPN. (2) Methods: The aims of this works are: (a) to summarize the potential mechanisms that could induce CIPN by the most relevant drugs (platinum, taxanes, vinca alkaloids, and bortezomib), with particular focus on the role of oxidative stress; (b) to summarize the current situation of prophylactic and treatment approaches; (c) to describe the action mechanisms of ozone therapy to modify oxidative stress and inflammation with its potential repercussions for CIPN; (d) to describe related experimental and clinical reports with ozone therapy in chemo-induced neurologic symptoms and CIPN; and (e) to show the main details about an ongoing focused clinical trial. (3) Results: A wide background relating to the mechanisms of action and a small number of experimental and clinical reports suggest that ozone therapy could be useful to prevent or improve CIPN. (4) Conclusions: Currently, there are no clinically relevant approaches for the prevention and treatment of stablished CIPN. The potential role of ozone therapy in this syndrome merits further research. Randomized controlled trials are ongoing.
- 10 March 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (6) , 2802
Open AccessModulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial
(1) Background: Chemotherapy-induced peripheral neuropathy (CIPN) decreases the quality of life of patients and can lead to a dose reduction and/or the interruption of chemotherapy treatment, limiting its effectiveness. Potential pathophysiological mechanisms involved in the pathogenesis of CIPN include chronic oxidative stress and subsequent increase in free radicals and proinflammatory cytokines. Approaches for the treatment of CIPN are highly limited in their number and efficacy, although several antioxidant-based therapies have been tried. On the other hand, ozone therapy can induce an adaptive antioxidant and anti-inflammatory response, which could be potentially useful in the management of CIPN. (2) Methods: The aims of this works are: (a) to summarize the potential mechanisms that could induce CIPN by the most relevant drugs (platinum, taxanes, vinca alkaloids, and bortezomib), with particular focus on the role of oxidative stress; (b) to summarize the current situation of prophylactic and treatment approaches; (c) to describe the action mechanisms of ozone therapy to modify oxidative stress and inflammation with its potential repercussions for CIPN; (d) to describe related experimental and clinical reports with ozone therapy in chemo-induced neurologic symptoms and CIPN; and (e) to show the main details about an ongoing focused clinical trial. (3) Results: A wide background relating to the mechanisms of action and a small number of experimental and clinical reports suggest that ozone therapy could be useful to prevent or improve CIPN. (4) Conclusions: Currently, there are no clinically relevant approaches for the prevention and treatment of stablished CIPN. The potential role of ozone therapy in this syndrome merits further research. Randomized controlled trials are ongoing.
- Open Access
- 26 November 2019
- Published by MDPI AG in Antioxidants
- Vol. 8 (12) , 588
Modulation of Oxidative Stress by Ozone Therapy in the Prevention and Treatment of Chemotherapy-Induced Toxicity: Review and Prospects
(1) Background: Cancer is one of the leading causes of mortality worldwide. Radiotherapy and chemotherapy attempt to kill tumor cells by different mechanisms mediated by an intracellular increase of free radicals. However, free radicals can also increase in healthy cells and lead to oxidative stress, resulting in further damage to healthy tissues. Approaches to prevent or treat many of these side effects are limited. Ozone therapy can induce a controlled oxidative stress able to stimulate an adaptive antioxidant response in healthy tissue. This review describes the studies using ozone therapy to prevent and/or treat chemotherapy-induced toxicity, and how its effect is linked to a modification of free radicals and antioxidants. (2) Methods: This review encompasses a total of 13 peer-reviewed original articles (most of them with assessment of oxidative stress parameters) and some related works. It is mainly focused on four drugs: Cisplatin, Methotrexate, Doxorubicin, and Bleomycin. (3) Results: In experimental models and the few existing clinical studies, modulation of free radicals and antioxidants by ozone therapy was associated with decreased chemotherapy-induced toxicity. (4) Conclusions: The potential role of ozone therapy in the management of chemotherapy-induced toxicity merits further research. Randomized controlled trials are ongoing.
- 26 November 2019
- Published by MDPI AG in Antioxidants
- Vol. 8 (12) , 588
Open AccessModulation of Oxidative Stress by Ozone Therapy in the Prevention and Treatment of Chemotherapy-Induced Toxicity: Review and Prospects
(1) Background: Cancer is one of the leading causes of mortality worldwide. Radiotherapy and chemotherapy attempt to kill tumor cells by different mechanisms mediated by an intracellular increase of free radicals. However, free radicals can also increase in healthy cells and lead to oxidative stress, resulting in further damage to healthy tissues. Approaches to prevent or treat many of these side effects are limited. Ozone therapy can induce a controlled oxidative stress able to stimulate an adaptive antioxidant response in healthy tissue. This review describes the studies using ozone therapy to prevent and/or treat chemotherapy-induced toxicity, and how its effect is linked to a modification of free radicals and antioxidants. (2) Methods: This review encompasses a total of 13 peer-reviewed original articles (most of them with assessment of oxidative stress parameters) and some related works. It is mainly focused on four drugs: Cisplatin, Methotrexate, Doxorubicin, and Bleomycin. (3) Results: In experimental models and the few existing clinical studies, modulation of free radicals and antioxidants by ozone therapy was associated with decreased chemotherapy-induced toxicity. (4) Conclusions: The potential role of ozone therapy in the management of chemotherapy-induced toxicity merits further research. Randomized controlled trials are ongoing.
- 1 September 2017
- Published by Elsevier in The American Journal of Surgery
- Vol. 214 (3) , 413-415
Selective packing for uncontrollable traumatic thoracic wall bleeding preserving cardiopulmonary function
- 1 September 2017
- Published by Elsevier in The American Journal of Surgery
- Vol. 214 (3) , 413-415
Selective packing for uncontrollable traumatic thoracic wall bleeding preserving cardiopulmonary function
- 1 August 2017
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 104 (2) , 458-464
Ozone Therapy Protects Against Rejection in a Lung Transplantation Model: A New Treatment?
- 1 August 2017
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 104 (2) , 458-464
Ozone Therapy Protects Against Rejection in a Lung Transplantation Model: A New Treatment?
- 7 May 2017
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 37 (5) , 2581-2586
Primary Non-Hodgkin’s Lymphoma of the Gallbladder: Α Population-based Analysis
Background/Aim: Primary Non-Hodgkin's lymphoma of the gallbladder (PNHL-GB) is extremely rare and data on clinical characteristics, optimal management and outcomes of these patients are limited to anecdotal reporting. We, therefore, sought to examine these patients using a population-based database. Materials and Methods: Surveillance, epidemiology, and end results (SEER) database was queried between 1973 and 2013. Results: One hundred and six cases with PNHL-GB were identified (mean age=70.5 ±15 years, whites 92%, male: female 1.03:1). The majority of patients had loco-regional disease (61%) and DLBCL histology (33%). Ninenty cases (85%) had undergone surgical resection, 6 (5.6%) received radiotherapy. Median overall survival (OS) of the entire cohort was 41 months with a 5-year survival rate of 40%. Patients receiving adjuvant RT had superior OS compared to surgery alone (140 ±27 vs. 86 ±16 months, respectively) and patients with DLBCL demonstrated lower survival compared to other histologies (13 vs. 53 months, respectively, p=0.034). Conclusion: Our study presents the largest dataset of PNHL-GB describing clinical features and outcomes of these patients in addition to summarizing the literature.
- 7 May 2017
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 37 (5) , 2581-2586
Primary Non-Hodgkin’s Lymphoma of the Gallbladder: Α Population-based Analysis
Background/Aim: Primary Non-Hodgkin's lymphoma of the gallbladder (PNHL-GB) is extremely rare and data on clinical characteristics, optimal management and outcomes of these patients are limited to anecdotal reporting. We, therefore, sought to examine these patients using a population-based database. Materials and Methods: Surveillance, epidemiology, and end results (SEER) database was queried between 1973 and 2013. Results: One hundred and six cases with PNHL-GB were identified (mean age=70.5 ±15 years, whites 92%, male: female 1.03:1). The majority of patients had loco-regional disease (61%) and DLBCL histology (33%). Ninenty cases (85%) had undergone surgical resection, 6 (5.6%) received radiotherapy. Median overall survival (OS) of the entire cohort was 41 months with a 5-year survival rate of 40%. Patients receiving adjuvant RT had superior OS compared to surgery alone (140 ±27 vs. 86 ±16 months, respectively) and patients with DLBCL demonstrated lower survival compared to other histologies (13 vs. 53 months, respectively, p=0.034). Conclusion: Our study presents the largest dataset of PNHL-GB describing clinical features and outcomes of these patients in addition to summarizing the literature.
- 1 January 2017
- Published by Elsevier in Journal of Surgical Research
- Vol. 207, 174-180
Primary appendiceal lymphoma: clinical characteristics and outcomes of 116 patients
- 1 January 2017
- Published by Elsevier in Journal of Surgical Research
- Vol. 207, 174-180
Primary appendiceal lymphoma: clinical characteristics and outcomes of 116 patients